Vice President at Aquilo Capital Management - San Francisco, California, United States
Aquilo Capital invests in drug development companies that harness the power of cutting-edge science to address urgent medical needs. We employ deep sector expertise and a disciplined, value-oriented process to identify extraordinary biotech companies with the potential to alter the practice of medicine in profound ways. In our view, these investment opportunities offer both substantial risk-adjusted returns as well as paradigm-changing therapeutics for patients and for society. Marc Schneidman, Founder & CIO, has over 20 years of dedicated investing experience across the biotechnology universe.